Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab-Reference-Cited by-同舟云学术

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

Published:2011-08-16 Issue:6 Volume:12 Page:468-475
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Koutras A K,Antonacopoulou A G,Eleftheraki A G,Dimitrakopoulos F-I,Koumarianou A,Varthalitis I,Fostira F,Sgouros J,Briasoulis E,Bournakis E,Bafaloukos D,Bompolaki I,Galani E,Kalogeras K T,Pectasides D,Fountzilas G,Kalofonos H P

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj201137.pdf

Reference31 articles.

1. Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1996; 1: 27–31.

2. Ferrara N . VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795–803.

3. Hicklin DJ, Ellis LM . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011–1027.

4. Shibuya M, Claesson-Welsh L . Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549–560.

5. Kerbel RS . Tumor angiogenesis. N Engl J Med 2008; 358: 2039–2049.

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastrointestinal Malignancy: Genetic Implications to Clinical Applications;Cancer Treatment and Research;2024

2. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer;Scientific Reports;2023-08-09

3. Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer;2023-05-03

4. Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment;CPT: Pharmacometrics & Systems Pharmacology;2022-08-04

5. Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study;Genes & Genomics;2022-06-29